AnHorn Medicines Co., Ltd.

AnHorn Medicines is a drug discovery platform company with a strong pipeline, offering therapies that target and degrade disease-causing proteins. Our mission is to develop new class of BIGPRO® (Bi-functional liGand induced PROteolysis) drugs under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.
We offer effective drug candidates and partner with world leading pharmaceutical companies to carry project into real-world studies. We leverage on AnHorn’s proprietary AIMCADD®, an AI-enabled platform, to turn innovation into new therapeutics – new opportunities to target difficult-to-treat and drug resisting diseases.